97682-44-5 | Irinotecan

Chemical type

• Topoisomerase I inhibitor prodrug

^[1]

• Camptothecin derivative

^[2]

Key properties

• Converted to active metabolite SN-38 by carboxylesterase
• Induces DNA damage and apoptosis
• Upregulates caspase-3, caspase-8, and caspase-9
• Down-regulates NF-κB
• May down-regulate p53 in single treatment

^[1]

• Prodrug converted to active metabolite SN-38

^[2]

• Prodrug activated by metabolic conversion
• Inhibits DNA topoisomerase I via SN-38 metabolite
• Widely used systemic chemotherapy

^[3]

• Chemotherapeutic agent for colorectal cancer
• Part of regimens like FOLFIRI
• Combination with capecitabine and 17-AAG for synergistic effects
• Treatment of HT-29 colon cancer cells

^[1]

• Combined with CAPEFOX regimen for Clinical responses of colorectal cancer (CRC) treatment

^[2]

• Treatment of colorectal cancer and other solid tumors
• Precursor drug delivering SN-38 activity

^[3]

Classification by use

• Chemicals used in cancer chemotherapy
• Chemicals used as topoisomerase inhibitors
• Chemicals used as apoptosis inducers

A trustworthy factory and manufacturer

1. [Cite:1] Combination effects of Irinotecan, irinotecan and 17-AAG on colorectal cancer cell line (HT-29), Annals of Medicine and Surgery, Volume 78, June 2022, 103850
2. [Cite:2] Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors, Iscience, Volume 28, Issue 12, 19 December 2025, 114202
3. [Cite:3] ABCG2-mediated SN-38 efflux drives resistance to Sacituzumab govitecan in urothelial carcinoma, Cancer Letters, Volume 640, 1 March 2026, 218254